Marixino (previously Maruxa)



This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Marixino. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Marixino.

For practical information about using Marixino, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 13/04/2018

Authorisation details

Product details
Marixino (previously Maruxa)
Agency product number
Active substance
memantine hydrochloride
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Alzheimer Disease
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
KRKA, d.d.
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Novo mesto
Šmarješka cesta 6
8501 Novo mesto

Product information

04/04/2018 Marixino (previously Maruxa) - EMEA/H/C/002658 - T/0013


  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

other antidementia drugs

Therapeutic indication

Treatment of patients with moderate to severe Alzheimer’s disease.

Assessment history

How useful was this page?

Add your rating